Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial

Chi, Kim N.; Higano, Celestia S.; Blumenstein, Brent; Ferrero, Jean-Marc; Reeves, James; Feyerabend, Susan; Gravis, Gwenaelle; Merseburger, Axel S.; Stenzl, Arnulf; Bergman, Andries M.; Mukherjee, Som D.; Zalewski, Pawel; Saad, Fred; Jacobs, Cindy; Gleave, Martin; de Bono, Johann S.

Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial

Autor(en):

Chi, Kim N.; Higano, Celestia S.; Blumenstein, Brent; Ferrero, Jean-Marc; Reeves, James; Feyerabend, Susan; Gravis, Gwenaelle; Merseburger, Axel S.; Stenzl, Arnulf; Bergman, Andries M.; Mukherjee, Som D.; Zalewski, Pawel; Saad, Fred; Jacobs, Cindy; Gleave, Martin; de Bono, Johann S.

Tübinger Autor(en):

Feyerabend, Susan
Stenzl, Arnulf

Erschienen in:

Lancet Oncology (2017), Bd. 18, H. 4, S. 473-485

Verlagsangabe:

Elsevier Science Inc

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/S1470-2045(17)30168-7

ISSN:

1474-5488